Digital Pharma: Pfizer expands European Twitter use
pharmafile | January 27, 2011 | News story | Medical Communications |Â Â Digital Pharma blog, Pfizer, TwitterÂ
Pfizer has expanded its use of Twitter with its French operations becoming the latest of its European subsidiaries to join the micro-blogging service.
Pfizer France joins a growing number of European accounts run by the pharma company, including ones for Spain, Turkey, Austria and Slovakia.
These accounts, along with Pfizer’s official corporate presence and local accounts for Mexico, Venezuela and China, are featured in the Digital Pharma blog’s links directory, whose Twitter section goes live today.
It also features new accounts from Sanofi, whose US arm began tweeting yesterday, and Novo Nordisk’s Copenhagen-based ‘corporate sustainability voice’ @novonordisktbl, which launched earlier this month.
The new Pfizer France account is so far taking fairly a cautious approach – it’s only following two other Twitter users, @pfizer_news and the French industry association @LeemFrance, and has only tweeted twice in the two weeks since joining.
But the move is indicative of how far pharma’s use of Twitter has come since November 2008, when Boehringer Ingelheim and Novartis became the first in the industry to join the social media service.
As the Digital Pharma links directory illustrates, it’s now not unusual to see accounts run on a corporate, local, function or campaign basis.
In terms of volume of accounts Pfizer looks to lead the pack, closely followed by Roche and Bayer, all of whom have a diverse range of accounts to their name.
Despite this diversity, companies have decided against following Novo Nordisk’s lead with @racewithinsulin to run a prescription product branded Twitter account.
Dominic Tyer is web editor for Pharmafocus and InPharm.com and the author of the Digital Pharma blog He can be contacted via email, Twitter or LinkedIn.
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …
